How is acoustic wave therapy performed?

During treatment, a small wand-like device uses directed sound waves to stimulate penile tissue and encourage blood flow, which can also speed up the healing process. Low-intensity shockwaves have also been shown to grow new blood vessels and improve blood flow in the penis, which is essential for erections. Have you ever experienced severe, persistent and chronic pain? This is due to a neurotransmitter called Substance P. This neurotransmitter is responsible for the perception of pain and for transmitting that information to the central nervous system.

The sound waves emitted through the AWT help reduce the concentration of substance P, thus reducing pain and inflammation. This treatment works very well for musculoskeletal pain that is slow to heal due to injury or trauma. acoustic wave therapy for ED, known as Shockwave or GAINSWave, stimulates the corpora cavernosa (arteries of the penis) and associated nerve tissue. Each Shockwave session begins with a topical anesthetic solution applied to the patient's genitals.

Because erectile tissue extends beyond the area of the penis, treatment will include the area under the testicles and down to the perineum, except in patients with prostate cancer. Different solutions with different strengths are used, depending on the patient's health and individual response to pain. If a patient is especially nervous about pain, a dorsal block of the penis can be used to completely block the nerve response during therapy. The emergency specialist will monitor the numbness to ensure that the effect wears off as soon as possible, 2 ½ to 4 hours.

Shockwave sound wave therapy has been used for years to successfully treat venous and soft tissue damage. This proven technology is now available to improve and repair the penis. It works by stimulating a mechanical response in the body. Mechanically, low-energy sound waves break the microplaque in the arteries and induce neovascularization, so more blood can be directed to the penis.

Patients experience increased sensitivity and firmer and longer lasting erections. In a review of 14 studies of men who received low-intensity extracorporeal acoustic wave (LI-ESWT) treatment for erectile dysfunction (ED), there was evidence that these men experienced improvements in their ED after LI-ESWT. acoustic wave therapy (AWT) is a mechanical stimulation that encourages natural healing processes in the body. The same acoustic wave therapy is now used for a similar effect on the blood vessels of the corpora cavernosa of the penis.

The acoustic wave works best for men who have mild to moderate erectile dysfunction, which usually means that medications such as Viagra work well or at least help. When the low-intensity acoustic wave is applied to an organ, they cause mechanical stress or microtrauma, which in turn, induce a healing response and improves blood supply. An acoustic wave therapy treatment plan usually includes six sessions, spaced two weeks apart, with three sessions a week, or three weeks, with two sessions a week. Cardiologists have shown that Acoustic Wave technology stimulates the growth of new blood vessels.

For even greater erectile rejuvenation, acoustic wave therapy can be combined with P-Shot (platelet-rich plasma), which adds a high concentration of growth factors to strategic areas according to a patented protocol. Extracorporeal shock wave therapy (ESWT) is a non-invasive treatment that involves passing high-frequency acoustic waves through the skin and into the muscle, bone or tissue for a therapeutic effect. Consider receiving GAINSWave or acoustic shockwave therapy and take advantage of the long-term effects of this innovative ED treatment. ED acoustic wave therapy is a regenerative approach that aims to restore the health and function of the penis, helping men regain a spontaneous and active sex life.

Acoustic wave therapy helps amplify these signals to promote faster healing and shorter recovery time. Low-intensity shockwave therapy on the penis may help men with severe erectile dysfunction (ED) who do not respond to conventional treatment with phosphodiesterase type 5 (PDE) inhibitors, according to data published here at the 26th Annual Congress of the European Urological Association. . .